Protect Your Portfolio Against Market Uncertainty
- Discover companies with rock-solid fundamentals in TipRanks' Smart Value Newsletter.
- Receive undervalued stocks, resilient to market uncertainty, delivered straight to your inbox.
Abeona Therapeutics ( (ABEO) ) has provided an update.
On May 9, 2025, Abeona Therapeutics entered into an agreement to sell a Rare Pediatric Disease Priority Review Voucher (PRV) for $155 million, awarded by the FDA following the approval of their biologics license application for ZEVASKYN™. The sale, expected to close following customary conditions, will provide Abeona with sufficient cash for over two years of operations without additional capital and positions the company for profitability in early 2026 as ZEVASKYN becomes available to patients in the third quarter of 2025.
The most recent analyst rating on (ABEO) stock is a Buy with a $16.00 price target. To see the full list of analyst forecasts on Abeona Therapeutics stock, see the ABEO Stock Forecast page.
Spark’s Take on ABEO Stock
According to Spark, TipRanks’ AI Analyst, ABEO is a Neutral.
Abeona Therapeutics faces substantial financial challenges with no current revenue and ongoing losses, impacting its overall score. However, the promising potential for FDA approvals and significant revenue opportunities from new therapies provide a positive outlook. Despite bullish technical signals, the high RSI suggests caution. The stock’s valuation remains unattractive due to its negative P/E ratio, but strong earnings call projections and adequate cash reserves offer some optimism for future performance.
To see Spark’s full report on ABEO stock, click here.
More about Abeona Therapeutics
Abeona Therapeutics Inc. is a commercial-stage biopharmaceutical company focused on developing cell and gene therapies for serious diseases. Their flagship product, ZEVASKYN™, is the first autologous cell-based gene therapy for treating wounds in patients with recessive dystrophic epidermolysis bullosa (RDEB). The company also develops adeno-associated virus (AAV)-based gene therapies for ophthalmic diseases and operates a cGMP manufacturing facility in Cleveland, Ohio.
Average Trading Volume: 1,359,135
Technical Sentiment Signal: Sell
Current Market Cap: $257.2M
For an in-depth examination of ABEO stock, go to TipRanks’ Stock Analysis page.